Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Merck
Boehringer Ingelheim
Mallinckrodt
Express Scripts

Last Updated: October 1, 2022

QVAR REDIHALER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Qvar Redihaler, and when can generic versions of Qvar Redihaler launch?

Qvar Redihaler is a drug marketed by Norton Waterford and is included in one NDA. There are eight patents protecting this drug.

This drug has two hundred and forty-eight patent family members in twenty-seven countries.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch® Generic Entry Outlook for Qvar Redihaler

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 7, 2028. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for QVAR REDIHALER
Drug Prices for QVAR REDIHALER

See drug prices for QVAR REDIHALER

DrugPatentWatch® Estimated Generic Entry Opportunity Date for QVAR REDIHALER
Generic Entry Date for QVAR REDIHALER*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
AEROSOL, METERED;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for QVAR REDIHALER

US Patents and Regulatory Information for QVAR REDIHALER

QVAR REDIHALER is protected by eight US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of QVAR REDIHALER is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting QVAR REDIHALER

Dose counter for inhaler having a bore and shaft arrangement
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Dose counter for inhaler and method for counting doses
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Breath actuated inhaler
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Metered-dose inhaler
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Inhaler
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-001 Aug 3, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-001 Aug 3, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-001 Aug 3, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-002 Aug 3, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-001 Aug 3, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for QVAR REDIHALER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-001 Aug 3, 2017 See Plans and Pricing See Plans and Pricing
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-002 Aug 3, 2017 See Plans and Pricing See Plans and Pricing
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-001 Aug 3, 2017 See Plans and Pricing See Plans and Pricing
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-002 Aug 3, 2017 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for QVAR REDIHALER

When does loss-of-exclusivity occur for QVAR REDIHALER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 08234098
Estimated Expiration: See Plans and Pricing

Austria

Patent: 6386
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0809477
Estimated Expiration: See Plans and Pricing

Canada

Patent: 82528
Estimated Expiration: See Plans and Pricing

China

Patent: 1657829
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 35199
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 6831
Estimated Expiration: See Plans and Pricing

Patent: 0970907
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 35199
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 41349
Estimated Expiration: See Plans and Pricing

Israel

Patent: 1256
Estimated Expiration: See Plans and Pricing

Japan

Patent: 46968
Estimated Expiration: See Plans and Pricing

Patent: 10523184
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 09010600
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 35199
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1475968
Estimated Expiration: See Plans and Pricing

Patent: 090127376
Estimated Expiration: See Plans and Pricing

Spain

Patent: 04818
Estimated Expiration: See Plans and Pricing

United Kingdom

Patent: 06999
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QVAR REDIHALER around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2011144326 See Plans and Pricing
Hong Kong 1221920 用於吸入器的劑量計數器 (DOSE COUNTERS FOR INHALERS) See Plans and Pricing
Spain 2534668 See Plans and Pricing
South Africa 201307992 DOSE COUNTERS FOR INHALERS, INHALERS AND SHAFTS THEREOF See Plans and Pricing
South Korea 101618937 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Medtronic
Colorcon
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.